PTC Therapeutics, Inc. (PTCT) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$66.61
Price Target
$89.67
Target Range
$50.00 — $120.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E8.6x
Forward PEG—
Implied Growth-108.9%
Median Target$89.00
Analyst Spread78.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$50
-24.9%
Consensus
$90
+34.6%
Bull Case
$120
+80.2%
PTCT Price Target Analysis
Updated May 7, 2026As of May 7, 2026, PTC Therapeutics, Inc. (PTCT) has a Wall Street consensus price target of $89.67, based on estimates from 26 covering analysts. With the stock currently trading at $66.61, this represents a potential upside of +34.6%. The company has a market capitalization of $5.52B.
Analyst price targets range from a low of $50.00 to a high of $120.00, representing a 78% spread in expectations. The median target of $89.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PTCT trades at a trailing P/E of 8.6x. Analysts expect EPS to grow -108.9% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+41.5%
Avg Forward P/E31.3x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SRPTSarepta Therapeutics, Inc. | $2.4B | $23.03 | $24.63 | +6.9% | Buy | 7.7x | 54 |
 BMRNBioMarin Pharmaceutical Inc. | $10.5B | $54.60 | $89.64 | +64.2% | Buy | 12.7x | 41 |
 RAREUltragenyx Pharmaceutical Inc. | $2.5B | $25.93 | $51.50 | +98.6% | Buy | — | 33 |
 ALNYAlnylam Pharmaceuticals, Inc. | $40.4B | $303.00 | $445.67 | +47.1% | Buy | 45.2x | 52 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.48 | $34.78 | +61.9% | Buy | 48.5x | 37 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 KRYSKrystal Biotech, Inc. | $8.5B | $288.89 | $332.75 | +15.2% | Buy | 38.3x | 17 |
 RYTMRhythm Pharmaceuticals, Inc. | $6.6B | $96.61 | $140.00 | +44.9% | Buy | — | 20 |
 LGNDLigand Pharmaceuticals Incorporated | $4.6B | $232.55 | $267.75 | +15.1% | Buy | 26.1x | 17 |
 PRAXPraxis Precision Medicines, Inc. | $7.6B | $337.95 | $544.40 | +61.1% | Buy | — | 16 |
Upside Potential Comparison
RAREBMRNACADPRAXALNYRYTMKRYSLGNDSee PTCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTCT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTCT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPTCT — Frequently Asked Questions
Quick answers to the most common questions about buying PTCT stock.
What is the PTCT stock price target for 2026?
The consensus Wall Street price target for PTCT is $89.67, representing 34.6% upside from the current price of $66.61. With 26 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is PTCT a buy, sell, or hold?
PTCT has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $89.67 implies 34.6% upside from current levels.
Is PTCT stock overvalued or undervalued?
PTCT's current price is $66.61 with a consensus target of $89.67 (34.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can PTCT stock go?
The most bullish Wall Street analyst has a price target of $120 for PTCT, while the most conservative target is $50. The consensus of $89.67 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PTCT stock?
PTCT is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 9 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PTCT stock forecast?
The 12-month PTCT stock forecast based on 26 Wall Street analysts shows a consensus price target of $89.67, with estimates ranging from $50 (bear case) to $120 (bull case). The median consensus rating is "Buy".
Should I buy PTCT stock?
Wall Street analysts are very optimistic on PTCT, with a "Buy" consensus rating and $89.67 price target (34.6% upside). 15 of 26 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PTCT price targets vary so much?
PTCT analyst price targets range from $50 to $120, a 78% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $89.67 consensus represents the middle ground.